Effects of 18F-AV1451 PET imaging in suncortical vascular impairment in patients with subcortical vascular cognitive impairment, Alzheimer's disease and normal controls

Trial Profile

Effects of 18F-AV1451 PET imaging in suncortical vascular impairment in patients with subcortical vascular cognitive impairment, Alzheimer's disease and normal controls

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Flortanidazole F18 (Primary) ; Florbetaben F18
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 24 Aug 2017 New trial record
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top